Amarin Corporation PLC

AMRN Healthcare Drug Manufacturers General

Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024. In the quarter to June 2026, revenue fell 42.0%, EPS grew 45.8% and free cash flow fell 60.2%, each against the same quarter a year earlier.

11.37 0.20 −1.73%
Market cap
$244.4M
P/E
0.0×
Fwd P/E
−398×
Dividend yield
—
F-score
7/9
Altman Z
−1.86
Beneish M
−3.26
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
1.50 1.36 1.40 1.78
P/FCF ratio
0.00 43.21 11.86 21.35
P/Operating CF
(26.80) 18.96 47.43 50.26
P/B ratio
0.74 0.63 0.67 0.75
EV/Sales
0.32 0.02 0.06 0.19
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(3.28) 0.78 0.52 2.28
Current Ratio
3.45 3.34 3.48 3.67
Net Debt/EBITDA
28.03 53.83 28.80 27.68
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(25.73%) (13.39%) (11.83%) (8.77%)
Free Cash Flow Yield
(6.43%) 2.31% 8.43% 4.68%
Free Cash Flow per Share
(0.61) 0.74 0.30 0.32
Book value per Share
22.09 22.13 21.45 21.31
Free Cash Flow
(12.70) 15.28 6.39 6.60
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates